An expert discusses how vitiligo patients commonly develop thyroid disease as a comorbidity and face increased skin cancer risk while highlighting the urgent need for new treatments beyond the single ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry’s decline of 1.3%. The stock has also outperformed the sector in the ...

Topical ruxolitinib also is approved for nonsegmental vitiligo in patients aged 12 years or older in the US.

In REACH3 (ClinicalTrials.gov identifier: NCT03112603), ruxolitinib was investigated versus best available therapy (BAT) for 3 years in patients with steroid-refractory/dependent chronic graft-vers ...

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study The following represents ...

In Europe, Opzelura ® (ruxolitinib) cream 15mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

That began to change last September, when ruxolitinib cream—developed specifically for vitiligo—was submitted for regulatory approval in China. Though not yet approved, investors are already eyeing ...

The actress said she hopes the NHS can start prescribing Ruxolitinib which is said to help people who have vitiligo. “My heart goes out to anyone who has this condition.

HealthDay News — Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves signs of underlying myelofibrosis in JAK inhibitor-naive ...